Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Controlled, Open Label, Multicenter, Phase II Study to Evaluate the Efficacy and Safety of CetuGEX™ Plus CT in Comparison to Cetuximab Plus CT in Patients With Stage III/IV Recurrent and/or Metastatic SCCHN

NCT02052960 is registered in ClinicalTrials.gov with Glycotope GmbH as lead sponsor.

NCT NCT02052960
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02052960 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Controlled, Open Label, Multicenter, Phase II Study to Evaluate the Efficacy and Safety of CetuGEX™ Plus CT in Comparison to Cetuximab Plus CT in Patients With Stage III/IV Recurrent and/or Metastatic SCCHN
Lead sponsor
Glycotope GmbH
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2014
Completion date
October 4, 2017
Enrollment
240 (actual)
Sites
34

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, squamous cell of head and neck